The DOI matches its Crossref record; 292 of the 292 references it cites were found in a registry or an index.
Apoptosis and Molecular Targeting Therapy in Cancer
Open accessAbstract
Apoptosis is the programmed cell death which maintains the healthy survival/death balance in metazoan cells. Defect in apoptosis can cause cancer or autoimmunity, while enhanced apoptosis may cause degenerative diseases. The apoptotic signals contribute into safeguarding the genomic integrity while defective apoptosis may promote carcinogenesis. The apoptotic signals are complicated and they are regulated at several levels. The signals of carcinogenesis modulate the central control points of the apoptotic pathways, including inhibitor of apoptosis (IAP) proteins and FLICE-inhibitory protein (c-FLIP). The tumor cells may use some of several molecular mechanisms to suppress apoptosis and acquire resistance to apoptotic agents, for example, by the expression of antiapoptotic proteins such as Bcl-2 or by the downregulation or mutation of proapoptotic proteins such as BAX. In this review, we provide the main regulatory molecules that govern the main basic mechanisms, extrinsic and intrinsic, of apoptosis in normal cells. We discuss how carcinogenesis could be developed via defective apoptotic pathways or their convergence. We listed some molecules which could be targeted to stimulate apoptosis in different cancers. Together, we briefly discuss the development of some promising cancer treatment strategies which target apoptotic inhibitors including Bcl-2 family proteins, IAPs, and c-FLIP for apoptosis induction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–292 of 292
Zellweger, T., Miyake, H., Cooper, S. R., Chi, K., Conklin, B., Monia, B. P., & Gleave, M. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29459-3 · Cited by 133
July, L. V., Beraldi, E., So, A., Fazli, L., Evans, K. G., English, J. C., & Gleave, M. E. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.223.3.3 · Cited by 132
Nuclear receptors in cell life and death
Altucci, L., & Gronemeyer, H. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00502-1 · Cited by 131
Nehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Mazumder, S., DuPree, E., & Almasan, A. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043481669 · Cited by 128
Identification of Genes That Mediate Sensitivity to Cisplatin
Niedner, H., Christen, R. D., Lin, X., Kondo, A., & Howell, S. B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1153 · Cited by 126
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib
Cusack, J. C. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00079-3 · Cited by 126
Ito, Y., Pandey, P., Place, A., Sporn, M. B., Gribble, G. W., Honda, T., Kharbanda, S. M., & Kufe, D. W. (2000) · PubMed · Cited by 125
The Epigenetics of Colorectal Cancer
Issa, J. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06706.x · Cited by 119
Targeting BCL‐2 family proteins to overcome drug resistance in non‐small cell lung cancer
Wesarg, E., Hoffarth, S., Wiewrodt, R. G., Kröll, M., Biesterfeld, S., Huber, C., & Schüler, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22977 · Cited by 116
The Role of dUTPase and Uracil-DNA Repair in Cancer Chemotherapy
Ladner, R. D. (2001) · Current Protein and Peptide Science · doi:10.2174/1389203013380991 · Cited by 116
Cytoplasmic dynein is associated with slow axonal transport.
Dillman, J. F., Dabney, L. P., & Pfister, K. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.141 · Cited by 116
Tanno, S., Yanagawa, N., Habiro, A., Koizumi, K., Nakano, Y., Osanai, M., Mizukami, Y., Okumura, T., Testa, J. R., & Kohgo, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1788 · Cited by 113
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.
Schultz, R. M., Patel, V. F., Worzalla, J. F., & Shih, C. (1999) · PubMed · Cited by 111
Apoptosis: molecular mechanisms and pathogenicity
Rastogi, R. P., R., & Sinha, R. P. (2010) · Technische Universität Dortmund · doi:10.17877/de290r-8930 · Cited by 106
Peták, I., Tillman, D. M., & Houghton, J. A. (2000) · PubMed · Cited by 106
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L., & Neckers, K. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.277 · Cited by 104
Jani, T. S., DeVecchio, J., Mazumdar, T., Agyeman, A., & Houghton, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091645 · Cited by 103
Russell, J. S., Burgan, W. E., Oswald, K. A., Camphausen, K. A., & Tofilon, P. J. (2003) · PubMed · Cited by 103
Gleave, M. E., & Miyake, H. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0474-0 · Cited by 102
Lee, K. B., Parker, R. J., Bohr, V. A., Cornelison, T. L., & Reed, E. (1993) · Carcinogenesis · doi:10.1093/carcin/14.10.2177 · Cited by 101
Pugacheva, E. N., Ivanov, A. V., Kravchenko, J. E., Kopnin, B. P., Levine, A. J., & Chumakov, P. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205704 · Cited by 101
Longley, D. B., Boyer, J. D., Allen, W. L., Latif, T., Ferguson, P., Maxwell, P. J., McDermott, U., Lynch, M., Harkin, D. P., & Johnston, P. G. (2002) · PubMed · Cited by 100
Youn, C.-K., Kim, M.-H., Cho, H.-J., Kim, H.-B., Chang, I. Y., Chung, M., & You, H. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0348 · Cited by 99
IAP antagonists: promising candidates for cancer therapy
Mannhold, R., Fulda, S., & Carosati, E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.003 · Cited by 98
Human Mutations That Confer Paclitaxel Resistance
Yin, S., Bhattacharya, R., & Cabral, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0674 · Cited by 98
Melton, D. W., Ketchen, A.-M., Núñez, F., Bonatti-Abbondandolo, S., Abbondandolo, A., Squires, S., & Johnson, R. T. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.3.395 · Cited by 96
DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.
Kashishian, A., Douangpanya, H., Clark, D., Schlachter, S. T., Eary, C. T., Schiro, J. G., Huang, H., Burgess, L. E., Kesicki, E. A., & Halbrook, J. (2003) · PubMed · Cited by 95
Thymidylate Synthase Pharmacogenetics in Colorectal Cancer
Marsh, S., & McLeod, H. L. (2001) · Clinical Colorectal Cancer · doi:10.3816/ccc.2001.n.018 · Cited by 95
Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3
Sato, N., Yamamoto, T., Sekine, Y., Yumioka, T., Junicho, A., Fuse, H., & Matsuda, T. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02941-8 · Cited by 95
Stingl, L., Stühmer, T., Chatterjee, M., Jensen, M. R., Flentje, M. P., & Djuzenova, C. S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605683 · Cited by 94
Bull, E. E. A., Dote, H., Brady, K. J., Burgan, W. E., Carter, D. J., Cerra, M. A., Oswald, K. A., Hollingshead, M. G., Camphausen, K. A., & Tofilon, P. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1212 · Cited by 94
c-Fos as a Proapoptotic Agent in TRAIL-Induced Apoptosis in Prostate Cancer Cells
Zhang, X., Zhang, L., Yang, H., Huang, X., Otu, H. H., Libermann, T. A., DeWolf, W. C., Khosravi‐Far, R., & Olumi, A. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1310 · Cited by 93
Houghton, J. A., Tillman, D. M., & Harwood, F. G. (1995) · PubMed · Cited by 93
Apoptosis: Silencing the death receptors
Tschopp, J., Martinon, F., & Hofmann, K. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80233-4 · Cited by 92
Cabral, F., Abraham, I., & Gottesman, M. M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4388 · Cited by 90
Danik, M., Chabot, J., Mercier, C., Benabid, A., Chauvin, C., Quirion, R., & Suh, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8577 · Cited by 88
Kato, T., Duffey, D. C., Ondrey, F. G., Dong, G., Chen, Z., Cook, J. A., Mitchell, J. B., & Waes, C. V. (2000) · Head & Neck · Cited by 88
Up‐regulated expression of cytoplasmic clusterin in human ovarian carcinoma
Xie, D., Lau, S. H., Sham, J. S. T., Wu, Q., Fang, Y., Liang, L., Che, L.-H., Zeng, Y., & Guan, X. (2004) · Cancer · doi:10.1002/cncr.20765 · Cited by 87
Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
Yamaguchi, R., Janssen, E. M., Perkins, G. A., Ellisman, M. H., Kitada, S., & Reed, J. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024102 · Cited by 85
Crossing paths: interactions between the cell death machinery and growth factor survival signals
Brumatti, G., Salmanidis, M., & Ekert, P. G. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0288-8 · Cited by 85
Identification of p53 genetic suppressor elements which confer resistance to cisplatin
Gallagher, W. M., Cairney, M., Schott, B., Roninson, I. B., & Brown, R. H. (1997) · Oncogene · doi:10.1038/sj.onc.1200813 · Cited by 83
Clinical update: proteasome inhibitors in hematologic malignancies
Richardson, P. G. G. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00080-x · Cited by 80
Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells
Chu, E., Voeller, D. M., Jones, K. L., Takechi, T., Maley, G. F., Maley, F., Segal, S., & Allegra, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.207 · Cited by 79
Vossio, S., Palescandolo, E., Pediconi, N., Moretti, F., Balsano, C., Levrero, M., & Costanzo, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205465 · Cited by 78
Pirollo, K. F., Hao, Z., Rait, A. S., Ho, C. W., & Chang, E. H. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5922 · Cited by 75
Kim, K. B., Lotan, R., Yue, P., Sporn, M. B., Suh, N., Gribble, G. W., Honda, T., Wu, G. S., Hong, W. K., & Sun, S. Y. (2002) · Molecular Cancer Therapeutics · Cited by 75
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation
Machida, H., Matsumoto, Y., Shirai, M., & Kubota, N. (2003) · International Journal of Radiation Biology · doi:10.1080/09553000310001626135 · Cited by 74
Liang, J., Huang, K., Cheng, Y., Hsu, H., Cheng, A., Hsu, C., Yeh, K., Wang, S., & Chang, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1637 · Cited by 73
Interaction of a Cyclin E Fragment with Ku70 Regulates Bax-Mediated Apoptosis
Mazumder, S., Plesca, D. C., Kinter, M. T., & Almasan, A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01448-06 · Cited by 71
Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells
Fulda, S., Jeremias, I., & Debatin, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207970 · Cited by 70
Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas
Parczyk, K., Pilarsky, C. P., Rachel, U., & Koch-Brandt, C. (1994) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01202200 · Cited by 70
Patel, M. P., Masood, A., Patel, P. S., & Chanan-Khan, A. A. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328331a7a4 · Cited by 69
Inhibitor of apoptosis proteins in hematological malignancies
Fulda, S. (2008) · Leukemia · doi:10.1038/leu.2008.329 · Cited by 67
Enmon, R. M., Yang, W.-H., Ballangrud, Å., Solit, D. B., Heller, G., Rosen, N. X., Scher, H. I., & Sgouros, G. (2003) · PubMed · Cited by 66
Aherne, G. W., Hardcastle, A., Raynaud, F. I., & Jackman, A. L. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00035-4 · Cited by 65
Longley, D. B., Ferguson, P., Boyer, J., Latif, T., Lynch, M., Maxwell, P., Harkin, D. P., & Johnston, P. G. (2001) · PubMed · Cited by 63
Gong, B., Chen, Q., Endlich, B., Mazumder, S., & Almasan, A. (1999) · PubMed · Cited by 63
Ayene, I. S., Ford, L. P., & Koch, C. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0130 · Cited by 63
Baker, M. (2010) · Nature · doi:10.1038/4641225a · Cited by 62
Goff, B. A., Ries, J., Els, L. P., Coltrera, M. D., & Gown, A. M. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5094 · Cited by 61
Gao, S., Wang, H., Lee, P., Melamed, J., Li, C. X., Zhang, F., Wu, H., Zhou, L., & Wang, Z. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01991 · Cited by 61
A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
Watanabe, Y., Koi, M., Hemmi, H., Hoshai, H., & Noda, K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2037 · Cited by 59
Mazumder, S., Gong, B., Chen, Q., Drazba, J. A., Buchsbaum, J. C., & Almasan, A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2398-2409.2002 · Cited by 58
Backus, H. H. J., Wouters, D., Ferreira, C. G., van Houten, V. M. M., Brakenhoff, R. H., Pinedo, H. M., & Peters, G. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00204-1 · Cited by 56
A Stress-Induced, Superoxide-Mediated Caspase-1 Activation Pathway Causes Plasma IL-18 Upregulation
Sekiyama, A., Ueda, H., Kashiwamura, S., Sekiyama, R., Takeda, M., Rokutan, K., & Okamura, H. (2005) · Immunity · doi:10.1016/j.immuni.2005.04.006 · Cited by 56
Cheung, C. H. A., Wu, S.-Y., Lee, T., Chang, C.-Y., Wu, J., Hsieh, H., & Chang, J.-Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012564 · Cited by 56
Koyama, S., Koike, N., & Adachi, S. (2001) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320000181 · Cited by 55
Korkolopoulou, P. A., Saetta, A. A., Levidou, G., Gigelou, F., Lazaris, A. C., Thymara, I., Scliri, M., Bousboukea, K., Michalopoulos, N. V., Apostolikas, N., et al. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02723.x · Cited by 54
Harashima, K., Akimoto, T., Nonaka, T., Tsuzuki, K., Mitsuhashi, N., & Nakano, T. (2005) · International Journal of Radiation Biology · doi:10.1080/09553000400029460 · Cited by 50
Wilson, T. R., Redmond, K. M., McLaughlin, K. M., Crawford, N., Gately, K. A., O'Byrne, K. J., Le-Clorrenec, C., Holohan, C., Fennell, D. A., Johnston, P. G., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.76 · Cited by 48
Expression and biological significance of c-FLIP in human hepatocellular carcinomas
Du, X., Bao, G., He, X., Zhao, H., Yu, F., Qiao, Q., Lu, J., & Ma, Q.-J. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-24 · Cited by 47
Webley, S. D., Hardcastle, A., Ladner, R. D., Jackman, A. L., & Aherne, G. W. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1358 · Cited by 46
BCL-2: found bound and drugged!
Letai, A. G. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.08.007 · Cited by 46
Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling
Harkin, D. P. (2000) · The Oncologist · doi:10.1634/theoncologist.5-6-501 · Cited by 46
Cartee, L., Smith, R. L., Dai, Y., Rahmani, M., Rosato, R. R., Almenara, J. A., Dent, P., & Grant, S. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12090-1 · Cited by 43
Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Fulda, S. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008784533107 · Cited by 41
DNA repair and synthetic lethality
Guo, G., Zhang, F., Gao, R., Delsite, R., Feng, Z., & Powell, S. N. (2011) · International Journal of Oral Science · doi:10.4248/ijos11064 · Cited by 40
Clusterin and IGFBPs as Antisense Targets in Prostate Cancer
Gleave, M. E., & Jansen, B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.020 · Cited by 39
Marx, D., Meden, H., Ziemek, T., Lenthe, T., Kühn, W., & Schauer, A. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10169-1 · Cited by 38
p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin
Lam, V., McPherson, J., Salmena, L., Lees, J., Chu, W., Sexsmith, E., Hedley, D. W., Freedman, M. H., Reed, J. C., Malkin, D. M., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(99)00102-2 · Cited by 36
Miyake, H., Hara, I., Yamanaka, K., Arakawa, S., & Kamidono, S. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68155-4 · Cited by 34
Biroccio, A., D’Angelo, C., Jansen, B., Gleave, M. E., & Zupi, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20295 · Cited by 34
Letai, A. G. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200903134 · Cited by 33
Miyake, H., Muramaki, M., Kurahashi, T., Yamanaka, K., Hara, I., Gleave, M. E., & Fujisawa, M. (2006) · Urology · doi:10.1016/j.urology.2006.03.017 · Cited by 32
Interactions of mammalian proteins with cisplatin-damaged DNA
Turchi, J. J., Henkels, K. M., Hermanson, I. L., & Patrick, S. M. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00145-2 · Cited by 29
Apoptosis by Antitumor Agents and Other Factors in Relation to Cell Cycle Checkpoints.
Kondo, S. (1995) · Journal of Radiation Research · doi:10.1269/jrr.36.56 · Cited by 29
Hsf1-Mediated Stress Response can Transiently Enhance Cellular Radioresistance
Kabakov, A. E., Malyutina, Y. V., & Latchman, D. S. (2006) · Radiation Research · doi:10.1667/rr3514.1 · Cited by 28
Immunopathology of apoptosis ?introduction and overview
Vaux, D. L. (1998) · Springer Seminars in Immunopathology · doi:10.1007/bf00787224 · Cited by 24
Dart, D. A., Picksley, S. M., Cooper, P. A., Double, J. A., & Bibby, M. C. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.1.115 · Cited by 16
Narine, K. A. D., Keuling, A. M., Gombos, R. B., Tron, V. A., Andrew, S. E., & Young, L. C. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.11.010 · Cited by 13
Chen, L., Chen, T.-H., Wen, P.-Y., Chou, C., Ying, T., Chang, S., Ma, G., & Chen, M. (2009) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(09)60266-7 · Cited by 4
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Apoptosis: A Target for Anticancer Therapy
Pfeffer, C., & Singh, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020448 · Cited by 1,542
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
Metadata
- Authors
- Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., & Sakuragi, N.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014-06-12
- Volume
- 2014
- Pages
- 1-23
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2096306846
- Cited by
- 1,121
- References
- 292
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.